Bariatric Surgery Reduces Cancer Risk in Adults With Nonalcoholic Fatty Liver Disease and Severe Obesity

被引:94
|
作者
Rustgi, Vinod K. [1 ,2 ]
Li, You [1 ,2 ]
Gupta, Kapil [1 ,2 ]
Minacapelli, Carlos D. [1 ,2 ]
Bhurwal, Abhishek [1 ,2 ]
Catalano, Carolyn [1 ,2 ]
Elsaid, Mohamed, I [1 ,2 ]
机构
[1] Rutgers Robert Wood Johnson Med Sch, Div Gastroenterol & Hepatol, New Brunswick, NJ 08901 USA
[2] Rutgers Robert Wood Johnson Med Sch, Ctr Liver Dis & Masses, 1 Robert Wood Johnson Pl,Med Educ Bldg,Room 466, New Brunswick, NJ 08901 USA
关键词
Metabolic Surgery; Hepatic Steatosis; Nonalcoholic Steatohepatitis; Roux-en-Y Gastric Bypass; BODY-MASS INDEX; AMERICAN ASSOCIATION; UNITED-STATES; CLINICAL ENDOCRINOLOGISTS; NONSURGICAL SUPPORT; COLORECTAL-CANCER; WEIGHT-LOSS; BURDEN; IMPACT; PREVENTION;
D O I
10.1053/j.gastro.2021.03.021
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BACKGROUND & AIMS: Nonalcoholic fatty liver disease (NAFLD) is associated with obesity and increased risk of cancer. The impacts of bariatric surgery on cancer risk in NAFLD patients are unknown. We investigated the effect of bariatric surgery on cancer risk in patients with NAFLD and severe obesity using the MarketScan database. METHODS: We conducted a retrospective cohort study of 18 to 64 years old newly diagnosed NAFLD patients with severe obesity between 2007 and 2017. We used Cox proportional hazard models to examine the association between bariatric surgery, modeled as a time-varying covariate, and the risks of any cancer and obesity-related cancer, while accounting for confounding using inverse probability of treatment weighting (IPTW). RESULTS: A total of 98,090 patients were included in the study, 33,435 (34.1%) received bariatric surgery. In those without surgery, 1898 incident cases of cancer occurred over 115,890.11 person-years of follow-up, compared with 925 cancer cases over 67,389.82 person-years among surgery patients (crude rate ratio, 0.84; 95% CI, 0.77- 0.91). The IPTW-adjusted risk of any cancer and obesity-related cancer was reduced by 18% (hazard ratio, 0.82; 95% CI, 0.76-0.89) and 25% (hazard ratio, 0.65; 95% CI, 0.56-0.75), respectively, in patients with versus without bariatric surgery. The adjusted risks of any cancer and obesity-related cancer were significantly lower in cirrhotic versus non-cirrhotic patients who underwent surgery. In cancer-specific models, bariatric surgery was associated with significant risk reductions for colorectal, pancreatic, endometrial, thyroid cancers, hepatocellular carcinoma, and multiple myeloma. CONCLUSION: Bariatric surgery was associated with significant reductions in the risks of any cancer and obesity-related cancer in NAFLD patients with severe obesity.
引用
收藏
页码:171 / +
页数:24
相关论文
共 50 条
  • [31] The Effects of Metabolic Surgery on Fatty Liver Disease and Nonalcoholic Steatohepatitis
    Clanton, Jesse
    Subichin, Michael
    SURGICAL CLINICS OF NORTH AMERICA, 2016, 96 (04) : 703 - +
  • [32] Obesity and nonalcoholic fatty liver disease: current perspectives
    Sarwar, Raiya
    Pierce, Nicholas
    Koppe, Sean
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2018, 11 : 533 - 542
  • [33] Obesity-Associated Nonalcoholic Fatty Liver Disease
    Yilmaz, Yusuf
    Younossi, Zobair M.
    CLINICS IN LIVER DISEASE, 2014, 18 (01) : 19 - +
  • [34] Nonalcoholic Fatty Liver Disease
    Wang, Xiao Jing
    Malhi, Harmeet
    ANNALS OF INTERNAL MEDICINE, 2018, 169 (09) : ITC65 - ITC80
  • [35] Association of Bariatric Surgery With Cancer Risk and Mortality in Adults With Obesity
    Aminian, Ali
    Wilson, Rickesha
    Al-Kurd, Abbas
    Tu, Chao
    Milinovich, Alex
    Kroh, Matthew
    Rosenthal, Raul J.
    Brethauer, Stacy A.
    Schauer, Philip R.
    Kattan, Michael W.
    Brown, Justin C.
    Berger, Nathan A.
    Abraham, Jame
    Nissen, Steven E.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2022, 327 (24): : 2423 - 2433
  • [36] The Future of Nonalcoholic Fatty Liver Disease Treatment
    Mazhar, Khurram
    MEDICAL CLINICS OF NORTH AMERICA, 2019, 103 (01) : 57 - +
  • [37] Nonalcoholic Fatty Liver Disease and Liver Fibrosis in Bariatric Patients: Tehran Obesity Treatment Study (TOTS)
    Barzin, Maryam
    Motamedi, Mohammad Ali Kalantar
    Khalaj, Alireza
    Serahati, Sara
    Khalili, Davood
    Morakabati, Arman
    Valizadeh, Majid
    Azizi, Fereidoun
    Hosseinpanah, Farhad
    Rakhshani, Nasser
    HEPATITIS MONTHLY, 2018, 18 (05)
  • [38] Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease in Adults
    Malinowski, Scott S.
    Byrd, Jennifer S.
    Bell, Allison M.
    Wofford, Marion R.
    Riche, Daniel M.
    PHARMACOTHERAPY, 2013, 33 (02): : 223 - 242
  • [39] Environmental Risk Factors for Liver Cancer and Nonalcoholic Fatty Liver Disease
    VoPham, Trang
    CURRENT EPIDEMIOLOGY REPORTS, 2019, 6 (01) : 50 - 66
  • [40] The Predictive Role of Parathyroid Hormone for Nonalcoholic Fatty Liver Disease following Bariatric Surgery
    Jamialahmadi, Tannaz
    Nematy, Mohsen
    Abdalla, Mohammed
    Jangjoo, Ali
    Goshayeshi, Ladan
    Kroh, Matthew
    Moallem, Seyed Adel
    Abbasifard, Mitra
    Sathyapalan, Thozhukat
    Sahebkar, Amirhossein
    JOURNAL OF NUTRITION AND METABOLISM, 2022, 2022